1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Chen Q, Guo Z, Liu S, et al. The cancer incidence and mortality among children and adolescents during the period of 2010-2014 in Henan Province, China. Cancer Med, 2019, 8(2): 814-823.
|
3. |
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet, 2014, 383(9928): 1561-1571.
|
4. |
Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev, 2015, 2015(3): CD011430.
|
5. |
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 2018, 378(22): 2078-2092.
|
6. |
Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous nonsmall cell lung cancer. J Clin Oncol, 2020, 38(14): 1505-1517.
|
7. |
Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase Ⅲ trial. J Thorac Oncol, 2020, 15(8): 1351-1360.
|
8. |
Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med, 2022, 386(21): 1973-1985.
|
9. |
Heather A, Wakelee, Moishe Liberman, et al. KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. 2023 ASCO Annual Meeting. Abstract #LBA100.
|
10. |
O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stageⅠB-ⅢA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol, 2022, 23(10): 1274-1286.
|
11. |
Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB-ⅢA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet, 2021, 398(10308): 1344-1357.
|
12. |
Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell, 2017, 169(4): 750-765.
|
13. |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
|
14. |
Rosner S, Reuss JE, Zahurak M, et al. Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer. Clin Cancer Res, 2023, 29(4): 705-710.
|
15. |
Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med, 2021, 27(3): 504-514.
|
16. |
Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol, 2020, 15(5): 816-826.
|
17. |
Zhang F, Guo W, Zhou B, et al. Three-year follow-up of neoadjuvant programmed cell death protein-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol, 2022, 17(7): 909-920.
|
18. |
Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: An open-label, single-arm phase Ⅱtrial. Nat Med, 2022, 28(10): 2155-2161.
|
19. |
Lee J, Chaft J, Nicholas A, et al. PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stageⅠB-ⅢB NSCLC: LCMC3 trial primary analysis. J Thorac Oncol, 2021, 16: S59–S61.
|
20. |
Reuss JE, Anagnostou V, Cottrell TR, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer, 2020, 8(2): e001282.
|
21. |
Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stageⅢA pN2 non-small-cell lung cancer: A multicenter phaseⅡ trial. J Clin Oncol, 2003, 21(9): 1752-1759.
|
22. |
Liang W, Cai K, Cao Q, et al. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Transl Lung Cancer Res, 2022, 11(9): 1742-1762.
|
23. |
Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol, 2019, 30(2): 219-235.
|
24. |
Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat, 2019, 46: 100644.
|
25. |
Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: More haste, less speed. Br J Cancer, 2018, 118(3): 312-324.
|
26. |
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score≥50. J Clin Oncol, 2021, 39(21): 2339-2349.
|
27. |
Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med, 2020, 383(14): 1328-1339.
|
28. |
Wang C, Qiao W, Jiang Y, et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. J Cell Physiol, 2020, 235(5): 4913-4927.
|
29. |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol, 2020, 21(11): 1413-1422.
|
30. |
Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage ⅢA non-small-cell lung cancer (NADIM phaseⅡtrial). J Clin Oncol, 2022, 40(25): 2924-2933.
|
31. |
Sun C, Liu Y, Zhang P, et al. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage ⅢA/ⅢB non-small cell lung cancer: A single-arm, phase 2 trial. J Cancer Res Clin Oncol, 2023, 149(2): 819-831.
|
32. |
Liu Z, Gao Z, Zhang M, et al. Real-world effectiveness and prognostic factors analysis of stagesⅠ-Ⅲ non-small cell lung cancer following neoadjuvant chemo-immunotherapy or neoadjuvant chemotherapy. Ann Thorac Cardiovasc Surg, 2022, 28(2): 111-120.
|
33. |
Dai F, Wu X, Wang X, et al. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study. Front Oncol, 2022, 12: 1022123.
|
34. |
Fei K, Guo G, Wang J, et al. Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study. Front Oncol, 2023, 13: 1145303.
|
35. |
Lhuillier C, Rudqvist NP, Elemento O, et al. Radiation therapy and anti-tumor immunity: Exposing immunogenic mutations to the immune system. Genome Med, 2019, 11(1): 40.
|
36. |
Taunk NK, Rimner A, Culligan M, et al. Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Transl Lung Cancer Res, 2017, 6(2): 178-185.
|
37. |
Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with durvalumab after chemoradiotherapy in stage ⅢNSCLC. N Engl J Med, 2018, 379(24): 2342-2350.
|
38. |
Upadhaya S, Neftelino ST, Hodge JP, et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat Rev Drug Discov, 2021, 20(3): 168-169.
|
39. |
Dickhoff C, Senan S, Schneiders FL, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: The INCREASE trial. BMC Cancer, 2020, 20(1): 764.
|
40. |
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer, 2018, 118(1): 9-16.
|
41. |
Huang Y, Goel S, Duda DG, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res, 2013, 73(10): 2943-2948.
|
42. |
Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med, 2019, 7(5): 387-401.
|
43. |
Lam TC, Tsang KC, Choi HC, et al. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lung Cancer, 2021, 159: 18-26.
|
44. |
Roy S. Herbst, Wu Y , et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resectedEGFR-mutated (EGFRm) stageⅠB-ⅢA non-small cell lung cancer (NSCLC). 2023 ASCO, abstract LBA 3#.
|
45. |
Pape M, Vissers PAJ, Beerepoot LV, et al. A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. Ther Adv Med Oncol, 2022, 14: 17588359221075495.
|
46. |
Heymach JV, Mitsudomi T, Harpole D, et al. Design and rationale for a phaseⅢ, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stagesⅡandⅢ non-small-cell lung cancer: The AEGEAN Trial. Clin Lung Cancer, 2022, 23(3): e247-e251.
|
47. |
Shun Lu, Lin Wu, Wei Zhang, et al. Perioperative toripalimab+platinum-doublet chemotherapy vs. chemotherapy in resectable stage Ⅱ/Ⅲ non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phaseⅢNEOTORCH study. 2023 ASCO Annual Meeting, Abstract #8501.
|
48. |
Akinboro O, Larkins E, Pai-Scherf LH, et al. FDA approval summary: Pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1-high NSCLC. Clin Cancer Res, 2022, 28(11): 2221-2228.
|
49. |
Addeo A, Friedlaender A, Banna GL, et al. TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol, 2021, 163: 103374.
|
50. |
Sesma A, Pardo J, Cruellas M, et al. From tumor mutational burden to blood T cell receptor: Looking for the best predictive biomarker in lung cancer treated with immunotherapy. Cancers (Basel), 2020, 12(10): 2974.
|
51. |
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol, 2020, 21(10): 1353-1365.
|
52. |
Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res, 2021, 27(17): 4685-4689.
|
53. |
Paz-Ares L, Langer CJ, Novello S, et al. Pembrolizumab (Pembro) plus platinum-based chemotherapy (Chemo) for metastatic nsclc: Tissue tmb (Ttmb) and outcomes in keynote-021, 189, and 407. Ann Oncol, 2019, 30: v917-v918.
|
54. |
Jee J, Lebow ES, Yeh R, et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med, 2022, 28(11): 2353-2363.
|